Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Rating) shares gapped up prior to trading on Friday . The stock had previously closed at $2.89, but opened at $2.96. Lexicon Pharmaceuticals shares last traded at $2.91, with a volume of 199,971 shares.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on LXRX. Jefferies Financial Group began coverage on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 7th. They issued a “hold” rating and a $3.00 target price for the company. StockNews.com began coverage on shares of Lexicon Pharmaceuticals in a research report on Thursday. They issued a “sell” rating for the company.
Lexicon Pharmaceuticals Price Performance
The company’s fifty day moving average price is $2.55 and its 200 day moving average price is $2.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 5.38 and a current ratio of 5.38. The firm has a market capitalization of $570.58 million, a price-to-earnings ratio of -4.85 and a beta of 1.33.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of LXRX. The Manufacturers Life Insurance Company boosted its stake in Lexicon Pharmaceuticals by 126.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 35,943 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 20,065 shares during the period. Great West Life Assurance Co. Can boosted its stake in Lexicon Pharmaceuticals by 705.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 37,343 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 32,708 shares during the period. BVF Inc. IL boosted its stake in Lexicon Pharmaceuticals by 14.1% during the 3rd quarter. BVF Inc. IL now owns 16,149,179 shares of the biopharmaceutical company’s stock valued at $38,758,000 after purchasing an additional 2,000,000 shares during the period. Virtu Financial LLC acquired a new position in Lexicon Pharmaceuticals during the 3rd quarter valued at about $32,000. Finally, Point72 Asset Management L.P. acquired a new position in Lexicon Pharmaceuticals during the 3rd quarter valued at about $8,672,000.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes.
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.